0001209191-24-005522.txt : 20240503 0001209191-24-005522.hdr.sgml : 20240503 20240503205105 ACCESSION NUMBER: 0001209191-24-005522 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240503 FILED AS OF DATE: 20240503 DATE AS OF CHANGE: 20240503 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ZANTE GREG CENTRAL INDEX KEY: 0001264949 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37355 FILM NUMBER: 24915292 MAIL ADDRESS: STREET 1: C/O SANGAMO BIOSCIENCES, INC STE-A-100 STREET 2: POINT RICHMOND TECH, 501 CANAL BLVD, CITY: RICHMOND STATE: CA ZIP: 94804 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Viking Therapeutics, Inc. CENTRAL INDEX KEY: 0001607678 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 461073877 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-704-4660 MAIL ADDRESS: STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2024-05-03 0 0001607678 Viking Therapeutics, Inc. VKTX 0001264949 ZANTE GREG C/O VIKING THERAPEUTICS, INC. 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121 0 1 0 0 Chief Financial Officer 1 Common Stock, par value $0.00001 per share 2024-05-03 4 M 0 4249 4.68 A 211610 D Common Stock, par value $0.00001 per share 2024-05-03 4 M 0 30000 4.88 A 241610 D Common Stock, par value $0.00001 per share 2024-05-03 4 S 0 3101 73.4881 D 238509 D Common Stock, par value $0.00001 per share 2024-05-03 4 S 0 45570 74.4447 D 192939 D Common Stock, par value $0.00001 per share 2024-05-03 4 S 0 17238 75.4868 D 175701 D Common Stock, par value $0.00001 per share 2024-05-03 4 S 0 847 76.0743 D 174854 D Stock Option (Right to Buy) 4.68 2024-05-03 4 M 0 4249 0.00 D 2021-03-31 2030-03-31 Common Stock 4249 4251 D Stock Option (Right to Buy) 4.88 2024-05-03 4 M 0 30000 0.00 D 2023-01-03 2032-01-03 Common Stock 30000 60000 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2024. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.97 to $73.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.98 to $74.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.985 to $75.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.995 to $76.135, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. 25% of the shares subject to the option vested or will vest on each one year anniversary of the grant date. /s/ Michael Morneau as Attorney-in-Fact 2024-05-03